Millions of ageing persons worldwide are afflicted by the neurological ailment known as Alzheimer's Disease (AD). In fact, according to recent data, the number of AD patients globally is expected to quadruple by 2050. As a result, the toll that AD takes on people, families, and society at large is swiftly increasing, highlighting the increasing need for cutting-edge treatments to halt the disease's course and enhance the lives of AD patients. Lifestyle interventions may be particularly well-positioned to assist those with AD and other forms of dementia, such as Mild Cognitive Impairment (MCI), as they offer a more sustainable change through motivated behavior, while also being relatively cost-effective and feasible to implement. Pharmacological treatments, however, remain a current area of research and an important component of many individuals' care.
